SPOTLIGHT: Organogenesis plans expansion

With the help of state funds, Organogenesis is beefing up its operations in Massachusetts. The company, which makes regenerative medicine products, says it was persuaded to stay and grow in Massachusetts because of the state's new program to encourage the biotech field. Release | Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.